Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | STP1002 |
| Synonyms | |
| Therapy Description |
STP1002 binds to and inhibits Tankyrase, which results in stabilization of AXIN and decreased Wnt/beta-catenin signaling, potentially leading to decreased cell proliferation and tumor growth (PMID: 35849876). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STP1002 | STP 1002|STP-1002 | Tankyrase Inhibitor 11 | STP1002 binds to and inhibits Tankyrase, which results in stabilization of AXIN and decreased Wnt/beta-catenin signaling, potentially leading to decreased cell proliferation and tumor growth (PMID: 35849876). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| APC Q1338* | colorectal cancer | sensitive | STP1002 | Preclinical - Cell culture | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 35849876). | 35849876 |
| APC S811* | colorectal cancer | sensitive | STP1002 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in colorectal cancer cell lines harboring APC S811* in culture and inhibited tumor growth in a cell line xenograft model (PMID: 35849876). | 35849876 |
| APC E853* APC T1556Nfs*3 | colorectal cancer | sensitive | STP1002 | Preclinical - Cell culture | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in a colorectal cancer cell line harboring APC E853* and APC T1556Nfs*3 in culture (PMID: 35849876). | 35849876 |
| APC E1309Dfs*4 | colorectal cancer | sensitive | STP1002 | Preclinical - Cell culture | Actionable | In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in a colorectal cancer cell line harboring APC E1309Dfs*4 in culture (PMID: 35849876). | 35849876 |
| APC R1450* | colorectal cancer | sensitive | STP1002 | Preclinical - Pdx | Actionable | In a preclinical study, STP1002 inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring APC R1450* (PMID: 35849876). | 35849876 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Completed | USA | 0 |
CKB BOOST